International Journal of Cancer Management

Published by: Kowsar

Association Between NAT2 Polymorphisms and Prostate Cancer

Mandana Hasanzad 1 , 2 , * , Seyed Amir Mohsen Ziaei 3 , Vahideh Montazeri 4 , Mahdi Afshari 5 , Seyed Hamid Jamaldini 1 , 2 , Mahdieh Imani 1 , Mahshid Sattari 1 , Leila Hashemian 1 , 2 , Seyed Rouhollah Kalantar Moaetamed 1 , 2 and Mohammad Samzadeh 1 , 4
Authors Information
1 Medical Genomics Research Center, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
2 Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
3 Urology and Nephrology Research Center (UNRC), Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
5 Department of Community Medicine, Zabol University of Medical Sciences, Zabol, Iran
Article information
  • Iranian Journal of Cancer Prevention: February 2017, 10 (2); e5716
  • Published Online: February 14, 2017
  • Article Type: Research Article
  • Received: February 16, 2016
  • Revised: May 7, 2016
  • Accepted: February 11, 2017
  • DOI: 10.5812/ijcp.5716

To Cite: Hasanzad M, Ziaei S A M, Montazeri V, Afshari M, Jamaldini S H, et al. Association Between NAT2 Polymorphisms and Prostate Cancer, Int J Cancer Manag. 2017 ; 10(2):e5716. doi: 10.5812/ijcp.5716.

Abstract
Copyright © 2017, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1): 9-29[DOI][PubMed]
  • 2. Caporaso N, Goldstein A. Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics. 1995; 5(2): 59-63[DOI][PubMed]
  • 3. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000; 9(1): 29-42[PubMed]
  • 4. Windmill KF, Gaedigk A, Hall PM, Samaratunga H, Grant DM, McManus ME. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci. 2000; 54(1): 19-29[DOI][PubMed]
  • 5. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993; 14(8): 1633-8[DOI][PubMed]
  • 6. Delomenie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics. 1996; 6(2): 177-85[DOI][PubMed]
  • 7. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta. 1988; 948(1): 37-66[DOI][PubMed]
  • 8. Hayes RB, Bi W, Rothman N, Broly F, Caporaso N, Feng P, et al. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis. 1993; 14(4): 675-8[DOI][PubMed]
  • 9. Risch A, Wallace DM, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet. 1995; 4(2): 231-6[DOI][PubMed]
  • 10. Amirrasouli H, Kazerouni F, Sanadizade M, Sanadizade J, Kamalian N, Jalali M, et al. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population. Urol J. 2010; 7(2): 99-104[PubMed]
  • 11. Tanguay S, Awde M, Brock G, Casey R, Kozak J, Lee J. Diagnosis and management of benign prostatic hyperplasia in primary care. Can Urol Assoc J. 2009; 3(3-S2): 92-100
  • 12. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3): 1215[DOI][PubMed]
  • 13. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics. 1995; 5(1): 1-17[DOI][PubMed]
  • 14. Tian FS, Shen L, Ren YW, Zhang Y, Yin ZH, Zhou BS. N-acetyltransferase 2 gene polymorphisms are associated with susceptibility to cancer: a meta-analysis. Asian Pac J Cancer Prev. 2014; 15(14): 5621-6[PubMed]
  • 15. Agundez JA, Martinez C, Olivera M, Gallardo L, Ladero JM, Rosado C, et al. Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk. Br J Cancer. 1998; 78(10): 1361-7[DOI][PubMed]
  • 16. Wadelius M, Autrup JL, Stubbins MJ, Andersson SO, Johansson JE, Wadelius C, et al. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics. 1999; 9(3): 333-40[DOI][PubMed]
  • 17. Srivastava DS, Mittal RD. Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: a pilot study in north Indian population. BMC Urol. 2005; 5: 12[DOI][PubMed]
  • 18. Hooker S, Bonilla C, Akereyeni F, Ahaghotu C, Kittles RA. NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans. Prostate Cancer Prostatic Dis. 2008; 11(4): 349-56[DOI][PubMed]
  • 19. Iguchi T, Sugita S, Wang CY, Newman NB, Nakatani T, Haas GP. MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status. In Vivo. 2009; 23(1): 7-12[PubMed]
  • 20. Rovito PJ, Morse PD, Spinek K, Newman N, Jones RF, Wang CY, et al. Heterocyclic amines and genotype of N-acetyltransferases as risk factors for prostate cancer. Prostate Cancer Prostatic Dis. 2005; 8(1): 69-74[DOI][PubMed]
  • 21. Hamasaki T, Inatomi H, Katoh T, Aono H, Ikuyama T, Muratani T, et al. N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men. Int J Urol. 2003; 10(3): 167-73[DOI][PubMed]
  • 22. Mittal RD, Srivastava DS, Mandhani A. NAT2 gene polymorphism in bladder cancer: a study from North India. Int Braz J Urol. 2004; 30(4): 279-85[DOI][PubMed]
  • 23. Osian G, Procopciuc L, Vlad L, Iancu C, Cristea PG, Mocan T, et al. NAT2 polymorphisms and sporadic colorectal cancer survival. J Gastrointestin Liver Dis. 2010; 19(4): 361-8[PubMed]
  • 24. Gong C, Hu X, Gao Y, Cao Y, Gao F, Mo Z. A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review. Med Oncol. 2011; 28(1): 365-76[DOI][PubMed]
  • 25. Costa S, Pinto D, Morais A, Vasconcelos A, Oliveira J, Lopes C, et al. Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population. Prostate. 2005; 64(3): 246-52[DOI][PubMed]
  • 26. Hein DW, Leff MA, Ishibe N, Sinha R, Frazier HA, Doll MA, et al. Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1*10) in combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study. Environ Mol Mutagen. 2002; 40(3): 161-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments